The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | A dual-targeting BCMA and CD19 FasTCAR-T (GC012F/AZD0120) as 1L therapy for newly diagnosed myeloma
Juan Du, MD, Changzheng Hospital, Shanghai, China, discusses two Phase I trials (NCT04935580, NCT05840107) evaluating the safety and efficacy of a dual-targeting BCMA and CD19 FasTCAR-T (GC012F/AZD0120) as a first-line (1L) treatment for newly diagnosed multiple myeloma (MM). The two studies demonstrated encouraging results, including high response rates, measurable residual disease (MRD) negativity, and a favorable safety profile. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
